非特发性肺纤维化间质性肺病中的端粒长度与免疫抑制
本研究为多中心回顾性队列分析,纳入纤维化过敏性肺炎、不可分类间质性肺病和结缔组织病相关间质性肺病患者,评估白细胞端粒长度与免疫抑制剂暴露对2年无移植生存的交互作用。结果显示,端粒长度低于正常第10百分位的纤维化过敏性肺炎和不可分类间质性肺病患者暴露于霉酚酸或硫唑嘌呤时死亡风险显著增加,而端粒长度不低于该阈值者无此差异。
要点
- 端粒长度低于正常第10百分位的fHP和uILD患者使用霉酚酸或硫唑嘌呤与生存期缩短相关。
- 端粒长度不低于第10百分位的患者中,免疫抑制剂暴露与生存无显著关联。
- CTD-ILD因事件率和端粒长度低百分位患病率低,未能进行亚组分析。
核心结论
- 与IPF类似,年龄校正端粒长度低于正常第10百分位的fHP和uILD患者暴露于免疫抑制时可能生存期缩短。
研究设计与样本
- 回顾性多中心队列分析,发现队列613例和复制队列325例,纳入fHP、uILD和CTD-ILD患者,来自五个中心。
- 通过定量PCR测量白细胞端粒长度,以年龄校正的正常百分位表示。
- 采用基于倾向评分的逆概率治疗加权,结合时依免疫抑制剂暴露的加权Cox比例风险回归评估2年无移植生存。
主要发现
- 发现队列中40%患者暴露于免疫抑制,22%患者端粒长度低于正常第10百分位。
- 发现队列中端粒长度低于第10百分位的fHP和uILD患者暴露于霉酚酸或硫唑嘌呤时死亡风险比HR 4.97(95%CI 2.26-10.92;p<0.001)。
- 复制队列中相应死亡风险比HR 4.90(95%CI 1.74-13.77;p=0.003)。
- 端粒长度不低于第10百分位患者中免疫抑制剂暴露与生存无差异。
- 端粒长度低于第10百分位与免疫抑制剂暴露存在显著交互作用(发现队列p交互=0.013;复制队列p交互=0.011)。
局限性
- CTD-ILD因事件率低和端粒长度低于第10百分位患病率低,未能进行亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies suggest a harmful pharmacogenomic interaction exists between short leukocyte telomere length (LTL) and immunosuppressants in idiopathic pulmonary fibrosis (IPF). It remains unknown if a similar interaction exists in non-IPF interstitial lung disease (ILD). METHODS: A retrospective, multicentre cohort analysis was performed in fibrotic hypersensitivity pneumonitis (fHP), unclassifiable ILD (uILD) and connective tissue disease (CTD)-ILD patients from five centres. LTL was measured by quantitative PCR for discovery and replication cohorts and expressed as age-adjusted percentiles of normal. Inverse probability of treatment weights based on propensity scores were used to assess the association between mycophenolate or azathioprine exposure and age-adjusted LTL on 2-year transplant-free survival using weighted Cox proportional hazards regression incorporating time-dependent immunosuppressant exposure. RESULTS: The discovery and replication cohorts included 613 and 325 patients, respectively. In total, 40% of patients were exposed to immunosuppression and 22% had LTL <10th percentile of normal. fHP and uILD patients with LTL <10th percentile experienced reduced survival when exposed to either mycophenolate or azathioprine in the discovery cohort (mortality hazard ratio (HR) 4.97, 95% CI 2.26-10.92; p<0.001) and replication cohort (mortality HR 4.90, 95% CI 1.74-13.77; p=0.003). Immunosuppressant exposure was not associated with differential survival in patients with LTL ≥10th percentile. There was a significant interaction between LTL <10th percentile and immunosuppressant exposure (discovery pinteraction=0.013; replication pinteraction=0.011). Low event rate and prevalence of LTL <10th percentile precluded subgroup analyses for CTD-ILD. CONCLUSION: Similar to IPF, fHP and uILD patients with age-adjusted LTL <10th percentile may experience reduced survival when exposed to immunosuppression.
引用
- Zhang D, Adegunsoye A, Oldham JM, et al. Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2023. PMID: 37591536. doi:10.1183/13993003.00441-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。